Program Book

of the tissues most commonly affected by NF-1. Because the multiple,
bright patchy spots were detected in 100% of cases under NIR reflectance
imaging.2) In NF-1 patients, to prove presence of abnormal pigment
accumulation which may originates from choroidal Schwann cells or
nevoid cells will lead to better understandings of disease.
1) Keilbauer CN, et al. IOVS 2006, 2)Yasunari T, et al. Lancet 2000
Financial disclosure. None
2340 OT8
VASOPROLIFERATIVE LESIONS (VPLS) OF THE RETINA
AND THE OPTIC DISC
Vicktoria Vishnevskia-Dai1, Josef Moisseiev1, Amir Elhalel1, Iris Moroz1 ,
Roth Sigal2, Mordechai Rosner1 (vivida65@gmail.com)
1. Goldschleger Eye Institute, Sheba Medical center, Sackler School of
medicine, Tel-Aviv University Israel.
2. Rabin Medical center, Sackler School of medicine, Tel-Aviv University
Israel.
Purpose. Vasoproliferative lesions (VPLs) of the Retina and the Optic Disc
consist of four rare clinical entities: Retinal capillary hemangioma, other
retinal vasoproliferative lesions, retinal cavernous hemangiom and retinal
arteriovenous communications (Wyburn-Mason syndrome).
Our purpose is to report our experience with the management of patients with VPLs.
Methods. Consecutive case series of 10 patients with VPLs treated at the
Sheba medical center, Tel Aviv University, between the years 2004-2011.
Results. The series included 14 eyes of 10 patients (8 males and 2
females). The average age of the patients was 40.2 years (9-74years). The
follow up time was 4-84 months (mean 29.8 months).
Five of the patients had associated systemic disease. Two patients had
associated ocular condition.
Five eyes needed observation only. Of the eyes that needed intervention
3 were injected with anti VEGF, 3 were treated with cryo-ablation, 3 were
treated with argon laser photocoagulation, one with trans papillary
thermo therapy and 3 eyes needed vitrectomy.
The final visual acuity was 6/6 or better in 8 eyes (57%) 6/12 or better in
11 eyes (78%) and less then 6/60 in 3 eyes (21%).
Conclusions. Vasoproliferative lesions of the retina and the optic disc are
rare ocular pathologies with a wide clinical spectrum of presentation.
Proper systemic workup and patient tailored management can prevent
ocular and systemic morbidity, and result in good visual acuity in most
of the patients.
Financial disclosure. None
2113 OT9
VITREORETINAL SURGERY FOR TRACTIONAL COMPLI-
CATIONS ASSOCIATED WITH JUXTAPAPILLARY COM-
BINED HAMARTOMA OF THE RETINA AND RETINAL
PIGMENT EPITHELIUM
Javier Elizalde (jem25@telefonica.net)
Ocular Oncology Service, Barraquer Institute, Barcelona, SPAIN
Purpose. To describe clinical features of tractional complications
associated with combined hamartoma of the retina and retinal pigment
epithelium (CHRRPE) and to discuss the surgical indications and
technique, and the functional outcome after vitreoretinal surgery.
Methods. Our Ocular Oncology database and the clinical data were
EYELID, CONJUNTIVA & ORBIT
Abstracts
73
reviewed. Microincisional vitreoretinal surgery with 23G instruments
was performed to relieve the tractional component when the patient
complained of progressive visual loss.
Results. Clinical findings indicating retinal traction associated with
CHRRPE include progressive distortion and displacement of the
neighboring retina, stretching of the blood vessels, telangiectasias,
retinal striae, exudation, superficial hemorrhages, retinal pigment
epithelium abnormalities and full-thickness retinal folds. Vitreoretinal
surgery usually improves the anatomical aspect of the retina although
the functional improvement can be limited.
Conclusions. Surgical dissection is partially effective in the treatment
of vitreomacular traction associated with CHRRPE because amblyopia,
long-standing intraretinal abnormalities and chronic photoreceptor
damage usually limit the functional outcome. Early detection and
intervention for cases presenting a recent vision loss are thought to
show more positive results.
Financial disclosure. None
206 OT10
RISK OF RADIATION RETINOPATHY IN PATIENTS WITH
ORBITAL AND OCULAR LYMPHOMA
Megha Kaushik, MBBS(hons) BSci(med)hons1, Jose S. Pulido1, MD
MS MPH, Khushboo K. Agrawal1, MD, Steven E. Schild2, MD, Scott
Stafford2, MD
(megha.ka@gmail.com)
1. Department of Ophthalmology
2. Department of Radiation Oncology
Mayo Clinic
Purpose. The aim of this study is to identify the risk of developing radiation
retinopathy at increasing radiation doses.
Methods. A 40 year retrospective review was performed of patients who
received external beam radiation therapy for ocular/orbital non-Hodgkin’s
lymphoma (NHL).
Results. Sixty-seven patients who had at least one ophthalmic follow up
examination were included in this study. Most patients were diagnosed
with NHL involving the orbit (52%). The patients received external beam
radiation therapy at doses between 1886 to 5400cGy (mean 3033 ± 782
cGy). 12% of patients developed radiation retinopathy with the mean time
to diagnosis of 60 ± 76 months. The mean radiation dose in patients with
retinopathy was 3309 ± 585cGy and the estimated retinal dose (derived by
formulae) was 3087 ± 1030cGy. The incidence of retinopathy increased with
dose. The mean visual acuity of the eyes that received radiation was worse
than the eyes that did not (p=0.027). More patients with post-radiation
retinopathy had comorbid diabetes mellitus type 2 compared to patients
without retinopathy (p=0.015). Other post-radiotherapy ocular findings in
our study included keratitis (7%), dry eyes (39%), and cataract (33%).
Conclusions. Radiation retinopathy is a known complication of therapy for
tumors within the orbit appears related to co-morbidities and dose. When
treating an orbital tumor, one should always use the lowest effective dose
and spare the eye to the greatest extent possible.
Financial disclosure. None
2324 OT11
VITREORETINAL LYMPHOMA TREATED BY INTRAVIT-
REAL INJECTIONS OF METHOTREXATE: 80 EYES OVER
14 YEARS
Jacob Pe’er, MD, Shahar Frenkel, MD, PhD (peer@hadassah.org.il)